Corvus Pharmaceuticals, Inc.

NasdaqGM:CRVS 주식 보고서

시가총액: US$515.4m

Corvus Pharmaceuticals 미래 성장

Future 기준 확인 2/6

Corvus Pharmaceuticals은 연간 수입과 매출이 각각 12.1%와 78.7% 증가할 것으로 예상되고 EPS는 연간 20%만큼 증가할 것으로 예상됩니다.

주요 정보

12.1%

수익 성장률

20.0%

EPS 성장률

Biotechs 수익 성장28.4%
매출 성장률78.7%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트13 Nov 2024

최근 미래 성장 업데이트

Recent updates

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Sep 02

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

수익 및 매출 성장 예측

NasdaqGM:CRVS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20263-50-9N/A4
12/31/20251-353N/A4
12/31/2024N/A-58-7N/A4
9/30/2024N/A-57-22-22N/A
6/30/2024N/A-23-21-21N/A
3/31/2024N/A-25-21-21N/A
12/31/2023N/A-27-24-24N/A
9/30/2023N/A-30-26-26N/A
6/30/2023N/A-39-28-28N/A
3/31/2023N/A-41-29-29N/A
12/31/2022N/A-41-27-27N/A
9/30/2022N/A-41-27-26N/A
6/30/2022N/A-37-28-28N/A
3/31/2022N/A-40-34-34N/A
12/31/2021N/A-43-37-37N/A
9/30/2021N/A-7-38-38N/A
6/30/2021N/A-6-37-37N/A
3/31/2021N/A-5-34-34N/A
12/31/2020N/A-6-35-35N/A
9/30/2020N/A-44-35-35N/A
6/30/2020N/A-46-38-38N/A
3/31/2020N/A-48-38-38N/A
12/31/2019N/A-47-37-37N/A
9/30/2019N/A-46-37-37N/A
6/30/2019N/A-46-38-37N/A
3/31/2019N/A-44-39-39N/A
12/31/2018N/A-47-41-41N/A
9/30/2018N/A-48-44-44N/A
6/30/2018N/A-51N/A-44N/A
3/31/2018N/A-54N/A-45N/A
12/31/2017N/A-56N/A-46N/A
9/30/2017N/A-55N/A-45N/A
6/30/2017N/A-52N/A-41N/A
3/31/2017N/A-46N/A-35N/A
12/31/2016N/A-36N/A-28N/A
9/30/2016N/A-31N/A-22N/A
6/30/2016N/A-24N/A-19N/A
3/31/2016N/A-36N/A-15N/A
12/31/2015N/A-31N/A-11N/A
9/30/2015N/A-25N/A-7N/A

애널리스트 미래 성장 예측

수입 대 저축률: CRVS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CRVS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CRVS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CRVS 의 수익(연간 78.7% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: CRVS 의 수익(연간 78.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: CRVS 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견